Mircea Dediu

11.9k total citations · 4 hit papers
55 papers, 6.6k citations indexed

About

Mircea Dediu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Mircea Dediu has authored 55 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 7 papers in Surgery. Recurrent topics in Mircea Dediu's work include Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (20 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Mircea Dediu is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (20 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Mircea Dediu collaborates with scholars based in Romania, Germany and United States. Mircea Dediu's co-authors include Tudor–Eliade Ciuleanu, Lesley Seymour, Frances A. Shepherd, Michael Smylie, P. Santabárbara, Sumitra Thongprasert, D. Johnston, Daniel de Castro, Andrea Bezjak and B. Findlay and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Mircea Dediu

51 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Tudor–Eliade Ciuleanu, Mircea Dediu et al. profile →
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Mircea Dediu

Since Specialization

Citations

This map shows the geographic impact of Mircea Dediu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mircea Dediu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mircea Dediu more than expected).

Fields of papers citing papers by Mircea Dediu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mircea Dediu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mircea Dediu. The network helps show where Mircea Dediu may publish in the future.

Co-authorship network of co-authors of Mircea Dediu

This figure shows the co-authorship network connecting the top 25 collaborators of Mircea Dediu. A scholar is included among the top collaborators of Mircea Dediu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mircea Dediu. Mircea Dediu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability 2024 ·BMC Proceedings ·Maximilian J. Hochmair, Mojca Unk, (unknown), Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, (unknown), Kersti Oselin, (unknown), (unknown), Marko Jakopović	0
2	The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung 2023 ·Current Oncology ·(unknown), Șerban Negru, Diana N. Ionescu, Mircea Dediu	6
3	Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT) 2022 ·Current Oncology ·(unknown), (unknown), Mircea Dediu, Ivan Donev, (unknown), (unknown), Tudor–Eliade Ciuleanu, Adam Płużański	6
4	Perspectives for Cancer Care and Research in Central and Eastern Europe 2022 ·Oncology Research and Treatment ·Christoph Zielinski, Tanja Čufer, Boštjan Šeruga, Jacek Jassem, Mircea Dediu, Christiane Thallinger	1
5	Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer 2017 ·Lung Cancer ·Kimio Yonesaka, Kenji Hirotani, Joachim von Pawel, Mircea Dediu, Shuquan Chen, Catherine Copigneaux, Kazuhiko Nakagawa	19
6	The Effect of Necitumumab in Combination with Gemcitabine-Cisplatin on Health-Related Quality of Life (HRQOL) and Tolerability: Squire Trial Patients with Epidermal Growth Factor Receptor (EGFR)-Expressing Squamous NSCLC Tumours 2016 ·Value in Health ·Martin Reck, Mark A. Socinski, Aleksandra Szczęsna, Mircea Dediu, Rodryg Ramlau, György Losonczy, Olivier Molinier, Christiane Schumann, Jacqueline Brown, (unknown), Nadia Chouaki, Nicholas Thatcher, Alexander Luft	1
7	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Nick Thatcher, Fred R. Hirsch, Alexander Luft, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, H. Depenbrock, Shivani Nanda, (unknown), Raffael Kurek, Luis Paz‐Ares, Mark A. Socinski	331
8	Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials 2014 ·Lung Cancer ·Giorgio V. Scagliotti, Cesare Gridelli, Filippo de Marinis, Michael Thomas, Mircea Dediu, Jean-Louis Pujol, C. Manegold, Belén San Antonio, Patrick Peterson, William J. John, Nadia Chouaki, Carla Visseren‐Grul, Luis Paz‐Ares	18
9	Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer 2014 ·Clinical Lung Cancer ·Joachim von Pawel, Jimmie H. Harvey, David R. Spigel, Mircea Dediu, Martin Reck, C. Cebotaru, Robin Humphreys, Matthew Gribbin, Norma Lynn Fox, D. Ross Camidge	81
10	Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer 2014 ·Clinical Lung Cancer ·Jean-Louis Pujol, Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Paolo Bidoli, J. Corral, Belén San Antonio, Nadia Chouaki, William J. John, Annamaria H. Zimmermann, Carla Visseren‐Grul, Cesare Gridelli	32
11	A Cost-Effectiveness Analyses of Using Sunitinib (SU) in First Line of Metastatic Renal Cancer in Romanian Jurisdiction 2013 ·Value in Health ·Florian Berghea, Jana Skoupá, T-E. Ciuleanu, Lucian Miron, Dana Lucia Stănculeanu, (unknown), Mircea Dediu, (unknown), Petr Hájek, (unknown), Jianwei Xuan	0
12	PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer breakdown → 2013 ·Journal of Clinical Oncology ·Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, J. Corral, Symantha Melemed, William J. John, Nadia Chouaki, Annamaria H. Zimmermann, Carla Visseren‐Grul, Cesare Gridelli	438
13	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial breakdown → 2012 ·The Lancet Oncology ·Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, J. Corral, Symantha Melemed, William J. John, Nadia Chouaki, Annamaria H. Zimmermann, Carla Visseren‐Grul, Cesare Gridelli	447
14	進行性NSCLC患者におけるカルボプラチンとパクリタキセルを併用した,TRAIL-R1アゴニスト単クローン抗体マパツムマブの無作為化第2相試験 2010 ·Journal of Clinical Oncology ·Joachim von Pawel, (unknown), David R. Spigel, Mircea Dediu, M. Reck, C. Cebotaru, (unknown), G. Gallant, (unknown), D. Ross Camidge	1
15	Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting 2009 ·Annals of Oncology ·Fausto Roila, Janusz Rolski, Rodryg Ramlau, Mircea Dediu, Mark W. Russo, Rajesh Bandekar, Steven M. Grunberg	27
16	XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy 2009 ·Journal of Thoracic Oncology ·U. Gatzemeier, Tudor–Eliade Ciuleanu, Mircea Dediu, (unknown), Heinz Lubenau, Auro del Giglio	63
17	The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: Results of a prospective observational study 2008 ·Lung Cancer ·Mircea Dediu, (unknown), (unknown), (unknown), (unknown), Aurelia Alexandru, (unknown), (unknown)	8
18	Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer 2008 ·Journal of Thoracic Oncology ·Corey J. Langer, Kenneth J. O’Byrne, Mark A. Socinski, (unknown), Krzysztof Leśniewski-Kmak, Martin Šmakal, Tudor–Eliade Ciuleanu, Sergey Orlov, Mircea Dediu, David F. Heigener, Amy J. Eisenfeld, Larissa Sandalic, F. B. Oldham, Jack W. Singer, Helen J. Ross	4
19	Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib. 2007 ·PubMed ·Mircea Dediu, (unknown), Aurelia Alexandru, (unknown), (unknown)	1
20	Adjuvant chemotherapy for radically resected non-small cell lung cancer 2004 ·Lung Cancer ·Mircea Dediu, (unknown), (unknown), Rodica Maricela Anghel, Ioan Cordoş, (unknown), (unknown), Aurelia Alexandru, Claudiu Nistor, (unknown), (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact